iCaspase9-transduced T cells

iCaspase9-transduced T cells are genetically engineered human T lymphocytes that express an inducible form of caspase 9 (iCasp9), which acts as a "suicide gene" safety switch. The system is designed to improve the safety of adoptive cell therapies such as CAR-T or donor lymphocyte infusions by allowing for rapid and selective elimination of the modified T cells in case of severe adverse events like graft-versus-host disease or cytokine release syndrome. Activation of the suicide switch is achieved by administering a small-molecule dimerizer drug (such as AP1903), which induces dimerization and activation of caspase 9, leading to rapid apoptosis in transduced cells. This approach has been shown to be effective in preclinical models and early-phase clinical trials for controlling potentially dangerous immune responses after cellular therapy[1][3][5][6].

Other names

inducible caspase 9-transduced T cellsiCasp9-modified T cellsiCasp-9-modified T cellsiCasp 9-modified T cellsCaspase-9 suicide gene-modified T cellsCaspase9 suicide gene-modified T cellsCaspase 9 suicide gene-modified T cells